GSK spends $900 million to raise India subsidiary stake

LONDON Tue Feb 5, 2013 2:43pm IST

A GlaxoSmithKline logo is seen outside one of its buildings in west London, February 6, 2008. REUTERS/Toby Melville/Files

A GlaxoSmithKline logo is seen outside one of its buildings in west London, February 6, 2008.

Credit: Reuters/Toby Melville/Files

Related Topics

Stocks

   

LONDON (Reuters) - GlaxoSmithKline Plc (GSK.L) has lifted its stake in its publicly-listed Indian consumer healthcare subsidiary to 72.5 percent from 43.2 percent, deepening its footprint in emerging markets and non-prescription products.

David Redfern, GSK's chief strategy officer, said on Tuesday the transaction - valued at 48 billion Indian rupees or 568 million pounds - would further increase exposure to a key emerging market.

"It is a significant vote of confidence in the long-term growth prospects of our consumer healthcare business in India," he added.

Britain's biggest drugmaker announced plans to acquire larger holdings in both its Indian and Nigerian consumer product businesses in November.

GSK offered 3,900 rupees per share for stock in Indian-based GlaxoSmithKline Consumer Healthcare Ltd (GLSM.NS) during a tender period that ran from January 17 to January 30, with final payment due on or before February 13. The open offer was managed by HSBC.

Shares in the Indian company were 2 percent lower at 3,750 rupees following news of the open offer result, while GSK was 0.5 percent higher, ahead of the group's full-year results on Wednesday.

The drugmaker's Indian arm sells popular brands such as health drink Horlicks, malt-based drink Boost and a multi-vitamin drink VitaHealth, which is marketed to women. It also markets OTC (over-the-counter) drugs such as paracetamol tablet Crocin, painkiller gel Iodex and acidity reliever Eno.

In Nigeria, GSK's plans to raise its holding in GlaxoSmithKline Consumer Nigeria Plc (GLAXOSM.LG) to 80 percent in a 15.4 billion naira deal are still progressing.

(Reporting by Ben Hirschler; Editing by Mark Potter)

FILED UNDER:
  • Most Popular
  • Most Shared

Coal

REUTERS SHOWCASE

Kotak-ING Deal

Kotak-ING Deal

Kotak Mahindra to acquire ING Vysya Bank  Full Article 

Ranbaxy in U.S.

Ranbaxy in U.S.

U.S. court overturns bid by Ranbaxy to block launch of rival generic drugs.  Full Article 

Edible Oil

Edible Oil

Indians get taste for branded edible oil as prices drop, incomes rise.  Full Article 

Financial Tech CEO

Financial Tech CEO

Financial Tech founder steps down as CEO   Full Article 

Canpotex Deal

Canpotex Deal

Canpotex signs potash sales deals to India  Full Article 

Tech Acquisition

Tech Acquisition

Tech Mahindra to buy U.S.-based network services operator for $240 million   Full Article 

Fired for Overbilling

Fired for Overbilling

Infosys unit's overbilling Apple led to exit of top execs - sources.  Full Article 

Real Estate Investment

Real Estate Investment

JM Financial subsidiary gets $87 mln from Vikram Pandit-led fund  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage